Enzyme:TPMT: Difference between revisions
From Pharmacopedia
More actions
| [unchecked revision] | [checked revision] |
MDElliottMD (talk | contribs) Consolidate enzyme entity page to canonical Pharmacopedia: sandbox location per Mark 2026-05-19. Full retrofitted version: history-first spine, collapsible-sortable substrate table, comprehensive-tables pointer, all PMIDs NCBI-eutils-verified, zero em-dashes. For CYP2D6/CYP3A4/CYP2C19 this replaces the earlier pre-retrofit draft with the full version; for the other 8 enzymes this is the first save at the canonical location. Resolves a cross-session sandbox-location duplication: the User:MDEll... |
MDElliottMD (talk | contribs) Add scope="col" to the data-table column headers for screen-reader association (ADA audit M5; designer-claude 2026-05-22) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 14: | Line 14: | ||
{| class="wikitable sortable" style="width:100%;" | {| class="wikitable sortable" style="width:100%;" | ||
! Substrate !! Therapeutic class !! TPMT relevance !! Clinical notes | ! scope="col" | Substrate !! scope="col" | Therapeutic class !! scope="col" | TPMT relevance !! scope="col" | Clinical notes | ||
|- | |- | ||
| '''[[Azathioprine]]''' || Immunosuppressant (IBD, transplant, autoimmune disease) || major || Prodrug; non-enzymatically converted to mercaptopurine after absorption, after which the mercaptopurine pharmacology applies. TPMT-deficiency myelosuppression risk is the same as for mercaptopurine. FDA labeling references TPMT (and NUDT15) testing. | | '''[[Azathioprine]]''' || Immunosuppressant (IBD, transplant, autoimmune disease) || major || Prodrug; non-enzymatically converted to mercaptopurine after absorption, after which the mercaptopurine pharmacology applies. TPMT-deficiency myelosuppression risk is the same as for mercaptopurine. FDA labeling references TPMT (and NUDT15) testing. | ||